Sifting through countless of stocks in the Biotechnology industry can be tedious, and sometimes two stocks are just too similar to judge which is the better investment. If you’re on the fence about investing in PTC Therapeutics, Inc., Ardelyx or Inc. because you’re not sure how they measure up, it’s important to compare them on a few factors before making your decision.

Read on to learn how PTC Therapeutics, Inc., Ardelyx and Inc. compare based on key financial metrics to determine which better meets your investment needs.

About PTC Therapeutics, Inc., Ardelyx and Inc.

PTC Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of medicines to children and adults living with rare disorders in the United States and internationally. The company provides Translarna and Emflaza for the treatment of Duchenne muscular dystrophy; Upstaza to treat aromatic l-amino acid decarboxylas (AADC) deficiency, a central nervous system disorder; Tegsedi and Waylivra for the treatment of rare diseases; and Evrysdi to treat spinal muscular atrophy (SMA) in adults and children. Its development pipeline products include Sepiapterin for the treatment of phenylketonuria; PTC518 splicing platform, which is being developed for the treatment of Huntington’s disease; and inflammation and ferroptosis platforms, including vatiquinone to treat Friedreich’s ataxia. The company distributes its products through third-party distributors. It has collaborations with F. Hoffman-La Roche Ltd., Hoffman-La Roche Inc., the SMA Foundation, National Taiwan University, Akcea Therapeutics, Inc., and Shiratori Pharmaceutical Co., Ltd. The company has license and collaboration agreement with Novartis Pharmaceuticals Corporation to develop PTC518 Huntington's disease program. It markets Upstaza, a gene therapy with the brand name Kebilidi in the United States. PTC Therapeutics, Inc. was incorporated in 1998 and is headquartered in Warren, New Jersey.

Ardelyx, Inc. discovers, develops, and commercializes medicines to treat unmet medical needs in the United States and internationally. The company offers IBSRELA, a minimally absorbed small molecule therapy for the treatment of patients with irritable bowel syndrome with constipation; and XPHOZAH, a phosphate absorption inhibitor to reduce serum phosphorus in adults with chronic kidney disease on dialysis. Ardelyx, Inc. was formerly known as Nteryx, Inc. and changed its name to Ardelyx, Inc. in June 2008. The company was incorporated in 2007 and is headquartered in Waltham, Massachusetts.

Latest Biotechnology and PTC Therapeutics, Inc., Ardelyx, Inc. Stock News

As of July 30, 2026, PTC Therapeutics, Inc. had a $6.3 billion market capitalization, compared to the Biotechnology median of $251.9 million. PTC Therapeutics, Inc.’s stock is down 10.5% in 2026, down 11.5% in the previous five trading days and up 53.22% in the past year.

Currently, PTC Therapeutics, Inc. does not have a price-earnings ratio. PTC Therapeutics, Inc.’s trailing 12-month revenue is $827.1 million with a -22.6% net profit margin. Year-over-year quarterly sales growth most recently was -76.8%. Analysts expect adjusted earnings to reach $1.320 per share for the current fiscal year. PTC Therapeutics, Inc. does not currently pay a dividend.

As of July 30, 2026, Ardelyx, Inc. had a $1.2 billion market cap, putting it in the 48th percentile of all stocks. Ardelyx, Inc.’s stock is down 15% in 2026, down 1.5% in the previous five trading days and up 19.43% in the past year.

Currently, Ardelyx, Inc. does not have a price-earnings ratio. Ardelyx, Inc.’s trailing 12-month revenue is $427.7 million with a -13.6% net profit margin. Year-over-year quarterly sales growth most recently was 27.5%. Analysts expect adjusted earnings to reach $-0.052 per share for the current fiscal year. Ardelyx, Inc. does not currently pay a dividend.

How We Compare PTC Therapeutics, Inc., Ardelyx and Inc. Stock Grades

Stock evaluation requires access to huge amounts of data and the knowledge and time to sift through it all, make sense of financial ratios, read income statements and analyze recent stock movements. AAII created A+ Investor, a robust data suite that condenses data research in an actionable and customizable way suitable for investors of all knowledge levels, to help investors streamline and work through such data.

AAII’s proprietary stock grades come with A+ Investor. These offer intuitive A‐F grades for each of five key investing factors: value, growth, momentum, earnings estimate revisions and quality. Here, we’ll take a closer look at PTC Therapeutics, Inc., Ardelyx and Inc.’s stock grades to see how they measure up against one another.

Learn more about A+ Investor here!

Sign Up to Receive a Free Special Report Showing How A+ Grades Can Help You Make Smarter Investment Decisions

PTC Therapeutics, Inc., Ardelyx and Inc. Stock Value Grades

Company	Ticker	Value
PTC Therapeutics, Inc.	PTCT	na
Ardelyx, Inc.	ARDX	F

Successful stock investing involves buying low and selling high, so stock valuation is an important consideration for stock selection.

Buying stocks that are going to go up typically means buying stocks that are undervalued in the first place, although momentum investors may argue that point.

AAII’s A+ Investor Value Grade derives from a stock’s value score. The Value Score is the percentile rank of the average of the percentile ranks of the price-to-sales ratio, price-earnings ratio, enterprise-value-to-EBITDA (EV/EBITDA) ratio, shareholder yield, price-to-book-value ratio and price-to-free-cash-flow ratio. The score is variable, meaning it can consider all six ratios or, should any of the six ratios not be valid, the remaining ratios that are valid. To be assigned a Value Score, stocks must have a valid (non-null) ratio and corresponding ranking for at least two of the six valuation ratios.

Stocks with a Value Score from 81 to 100 are considered deep value, those with a score between 61 and 80 are a good value and so on.

PTC Therapeutics, Inc. does not have a meaningful Value Score. Ardelyx, Inc. has a Value Score of 17, which is Ultra Expensive.

The Value Stock Winner: No Clear Winner

Neither PTC Therapeutics, Inc., Ardelyx or Inc. has a high enough value grade to be considered a “winner.” Investors who are considering these companies should do additional due diligence and research to see if either could be a good addition to their portfolio. It’s important to look at a wide range of financial metrics in order to determine if PTC Therapeutics, Inc., Ardelyx or Inc. is the better investment when it comes to value.

PTC Therapeutics, Inc., Ardelyx and Inc.’s Quality Grades

Company	Ticker	Quality
PTC Therapeutics, Inc.	PTCT	F
Ardelyx, Inc.	ARDX	D

Like the Value Grade, AAII’s A+ Investor Quality Grade comes from the percentile rank of key metrics. Specifically, the Quality Score is the percentile rank of the average of the percentile ranks of return on assets (ROA), return on invested capital (ROIC), gross profit relative to assets, buyback yield, change in total liabilities to assets, accruals, Z double prime bankruptcy risk (Z) score and the F-Score.

The score is variable, meaning it can consider all eight measures or, should any of the eight measures not be valid, the remaining measures that are valid. To be assigned a Quality Score, stocks must have a valid (non-null) measure and corresponding ranking for at least four of the eight quality measures.

The Quality Score is used to assess the underlying “quality” of a particular stock. A higher-quality stock possesses traits associated with upside potential and reduced downside risk. Backtesting of the Quality Grade shows that stocks with higher grades, on average, outperformed stocks with lower grades over the period of 1998 through 2019.

Stocks receive better grades (higher scores) for having higher scores for the quality subcomponents and worse grades (lower scores) for lower scores for the subcomponents.

PTC Therapeutics, Inc. has a Quality Score of 8, which is Very Weak. Ardelyx, Inc. has a Quality Score of 27, which is Weak.

The Quality Stock Winner: No Clear Winner

Neither PTC Therapeutics, Inc., Ardelyx or Inc. has a high enough Quality Grade to be considered a “winner.” Investors who are considering these companies should do additional due diligence and research to see if either could be a good addition to their portfolios. It’s important to look at a wide range of financial metrics in order to determine if PTC Therapeutics, Inc., Ardelyx or Inc. is the better investment when it comes to quality.

PTC Therapeutics, Inc., Ardelyx and Inc.’s Momentum Grades

Company	Ticker	Momentum
PTC Therapeutics, Inc.	PTCT	B
Ardelyx, Inc.	ARDX	C

Momentum grades help to uncover stocks experiencing anomalously high rates of return; research finds that stocks with high relative levels of momentum tend to outperform, whereas those with low levels of momentum tend to continue underperforming. Momentum is based on the price change of a stock over a specified period relative to all other stocks.

Typically, AAII looks at the weighted relative strength over the trailing four quarters. The weighted four-quarter relative strength rank is the relative price change for each of the past four quarters. The most recent quarterly price change is given a weight of 40% and each of the three previous quarters are given a weighting of 20%.

PTC Therapeutics, Inc. has a Momentum Score of 78, which is Strong. Ardelyx, Inc. has a Momentum Score of 46, which is Average.

The Momentum Grade Winner: PTC Therapeutics, Inc.

As you can clearly see from the Momentum Grade breakdown above, PTC Therapeutics, Inc. is considered to have stronger momentum compared to Ardelyx, Inc.. For those specifically looking for companies that have stronger momentum compared to other companies in the same industry, PTC Therapeutics, Inc. could be a good stock to invest in. However, it’s important for investors to analyze multiple factors based on a wide range of metrics before deciding whether to buy.

Other PTC Therapeutics, Inc., Ardelyx and Inc. Grades

In addition to Momentum, Quality and Value, A+ Investor also provides grades for Growth and Estimate Revisions.

Earnings estimate revisions scores take into account the magnitude of a company’s earnings surprise in its last two reported fiscal quarters. Often, surprises beget further surprises‐or at least continued sales growth (the exact opposite is generally true, too).

Growth investing builds on the idea that stocks of companies exhibiting strong, consistent and prolonged growth outperform those of slower-growth companies. AAII measures growth through consistency of annual sales growth, five-year sales growth rankings adjusted for extreme levels, and consistency of positive annual cash from operations.

These 2 key factors, when combined with the above, provide a holistic view into a particular stock. Further, by joining A+ Investor you can see whether PTC Therapeutics, Inc., Ardelyx and Inc. pass any of our 60+ stock screens that have outperformed the market since their creation.

So, Which Is the Better Investment, PTC Therapeutics, Inc., Ardelyx or Inc. Stock?

Overall, PTC Therapeutics, Inc. stock has a Value Score of , Momentum Score of 78 and Quality Score of 8.

Ardelyx, Inc. stock has a Value Score of 17, Momentum Score of 46 and Quality Score of 27.

Comparing PTC Therapeutics, Inc., Ardelyx and Inc.’s grades, scores and metrics can act as a solid basis to determine whether they may be a good investment or not. You’ll also want to look at your portfolio’s asset allocation as well as your risk tolerance and financial goals to see if either of these stocks would make a good fit for you. AAII can help you figure out which investments align with your individual needs and preferences.

Investors are encouraged to do their own due diligence and research. In this way, individuals can effectively become managers of their own assets‐without having to rely on others for financial independence. You can count on AAII for timeless articles on financial planning and stock-picking, unbiased research and actionable analysis.

A+ Investor adds to our qualitative teaching with a powerful data suite to help you whittle down investment choices to find stocks, exchange-traded funds (ETFs) or mutual funds that meet your needs.

AAII Disclaimer

We make no representations or warranties that any investor will, or is likely to, achieve profits similar to those shown, because past, hypothetical or simulated performance is not necessarily indicative of future results. Before making an investment decision, you should consider your circumstances and whether the information on our content is applicable to your situation. This information was prepared in good faith, and we accept no liability for any errors or omissions. The full disclaimer can be read here.